My top 3 ASX shares to consider buying before April

Here are three vastly different companies that each offer a tantalising opportunity right now.

| More on:
A young man wearing glasses writes down his stock picks in his living room.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 Index (ASX: XJO) is up 11.6% over the past year. Yet, I still believe there are top deals among ASX shares in this market. Yes, there are opportunities to discover even when the Australian share market is around all-time highs.

As April draws near (that was quick!), it's as good of a time as any to trawl through what is on offer. Despite headlines of a 'per capita recession' and whispers of an 'official recession' on the horizon, I will continue putting my money to work in quality companies — letting long-term compounding outweigh any temporary instability.

Here are a few ASX shares that meet my criteria for buying ahead of April this year.

Wonderful company at a fair price

The top echelon of companies usually trade on lofty valuations — everyone already knows how great they are. It makes it incredibly challenging to scoop up shares in such companies at a price that provides a margin of safety.

Occasionally, something that shatters a company's once-pearly perception — a rumour, a scathing report, or an innocent misstep — can occur. The reaction can be magnitudes greater than the actual issue, partially because the business loses that 'golden 'golden child' sheen.

In my view, Resmed CDI (ASX: RMD) is one such company. At a price-to-earnings (P/E) ratio of 31, the medical device maker's asking price is no tall order relative to its former glory.

The popularity of weight loss medications, such as Ozempic, has induced a slimming down of the Resmed share price. However, the market for sleep apnea treatments remains vast. Given the company's track record for growth, I'd happily buy more of this ASX share before the month ends.

A top ASX share with pricing power

A sensational FY23 full-year result has put this growth share on my radar. In my opinion, the combination of rapid growth and pricing power makes Life360 Inc (ASX: 360) highly attractive.

Companies that aren't yet generating profits can be hard to value. Nonetheless, the United States software maker appears to be heading in the right direction as it raises prices across its subscriber base.

For example, average revenue per 'paying circle' (essentially a family) rose 25% year-on-year amid the price increases. Positively, global paying circles still grew by 21% despite asking customers to pay more for the offering — evidence that Life360 wields some strong pricing power.

Furthermore, with 61 million global monthly active users, the runway for growth still seems lengthy. This ASX share is currently valued at a market capitalisation of $2.58 billion.

A winner from rate cuts

The third and final investment I'm contemplating this month is a bonafide value-style buy.

Famed value investor Benjamin Graham was known for his tendency to buy companies trading below their book value. This means the company's market capitalisation is less than its net assets, and Rural Funds Group (ASX: RFF) is an ASX share meeting this criteria.

The real estate investment trust (REIT) holds $1.9 billion of farmland and other agricultural assets. To do so, Rural Funds has taken on $701 million worth of debt to fund the purchase and improvement of property.

Because of this, the company stands to benefit if interest rates begin to fall later this year. Approximately one-fifth of the REIT's revenue was consumed by finance costs in the first half. Any reduction in interest expense will flow down to the bottom line of this ASX share.

Motley Fool contributor Mitchell Lawler has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Life360 and ResMed. The Motley Fool Australia has positions in and has recommended ResMed and Rural Funds Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

Happy young couple saving money in piggy bank.
Opinions

Want to start investing in ASX shares? Here's what I'd buy

This is where I’d begin to put my money in the stock market.

Read more »

People of different ethnicities in a room taking a big selfie, symbolising diversification.
Opinions

Want diversification? Get it instantly with these ASX 200 shares

Some businesses offer a lot more diversification than others.

Read more »

A happy man and woman on a computer at Christmas, indicating a positive trend for retail shares.
Opinions

2 ASX 200 shares I'd want to receive as a present today

Merry Christmas! Are there any stocks under your tree?

Read more »

Young boy in business suit punches the air as he finishes ahead of another boy in a box car race.
Opinions

Why I think these 2 ASX 300 stocks will beat the market in 2025

I’m very optimistic about a few ASX growth shares.

Read more »

A businessman compares the growth trajectory of property versus shares.
Opinions

What's the outlook for shares vs. property in 2025?

The experts have put out their new year predictions...

Read more »

Cheerful boyfriend showing mobile phone to girlfriend in dining room. They are spending leisure time together at home and planning their financial future.
Opinions

My ASX share portfolio is up 30% this year! Here's my plan for 2025

The best investing plans shouldn't need too many updates.

Read more »

Man in an office celebrates at he crosses a finish line before his colleagues.
Opinions

These stocks made my share portfolio a market-beater in 2024

Beating the market is the least important takeaway from this year.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Opinions

2 underappreciated ASX 200 shares to buy now

Investors may be undervaluing these ASX 200 shares heading into 2025, according to this expert.

Read more »